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Background
International guidelines for management of septic shock recommend that dopamine or norepinephrine are 
preferable to epinephrine. However, no large comparative trial has yet been done.
Methods
Objective: To compare the effi   cacy and safety of norepinephrine plus dobutamine (whenever needed) with those of 
epinephrine alone in septic shock.
Design: Prospective, multicenter, randomized, double-blind study.
Setting: 19 participating intensive care units in France.
Subjects: 330 adult patients with septic shock. Inclusion criteria were the presence for less than 7 days of: evidence 
of infection; at least 2 of the 4 criteria of systemic infl  ammatory response syndrome (SIRS); and at least two signs of 
tissue hypoperfusion or organ dysfunction. Additionally, subjects had to have had to meet the three following criteria 
for less than 24 hours: systolic blood pressure less than 90 mm Hg or mean BP less than 70 mm Hg; administration of 
fl  uid bolus of at least 1000 mL or capillary wedge pressure between 12 and 18 mm Hg; and need for more than 15 μg 
per kg bodyweight per min of dopamine or any dose of epinephrine or norepinephrine. Specifi  c exclusion criteria 
were established to ensure other causes of shock were excluded.
Intervention: Participants were assigned to receive epinephrine (n=161) or norepinephrine plus dobutamine (n=169), 
which were titrated to maintain mean blood pressure at 70 mm Hg or more.
Outcomes: The primary outcome was 28-day all-cause mortality. The secondary outcomes were survival distribution 
from randomization to day 90; mortality rates at day 7, 14, at discharge from intensive care and from hospital, and 
at day 90; systemic hemodynamics; arterial pH and lactate; SOFA score; time to hemodynamic success and time to 
vaspressor withdrawal. Analyses were by intention to treat.
Results
There were no patients lost to follow-up; one patient withdrew consent after 3 days. At day 28, there were 64 (40%) 
deaths in the epinephrine group and 58 (34%) deaths in the norepinephrine plus dobutamine group (p=0.31; relative 
risk 0.86, 95% CI 0.65-1.14). There was no signifi  cant diff  erence between the two groups in mortality rates at discharge 
from intensive care (75 [47%] deaths vs. 75 [44%] deaths, p=0.69), at hospital discharge (84 [52%] vs. 82 [49%], p=0.51), 
and by day 90 (84 [52%] vs. 85 [50%], p=0.73), time to hemodynamic success (log-rank p=0.67), time to vasopressor 
withdrawal (log-rank p=0.09), and time course of SOFA score. Rates of serious adverse events were also similar.
Conclusions
There is no evidence for a diff  erence in effi   cacy and safety between epinephrine alone and norepinephrine plus 
dobutamine for the management of septic shock. (ClinicalTrials.gov number, NCT00148278).
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Surviving sepsis campaign guidelines recommend nor-
epinephrine or dopamine as the ﬁ   rst line vasoactive 
agents for the management of hypotension in septic 
shock. In contrast, epinephrine is relegated to second or 
third-line therapy due to adverse eﬀ  ects,  including 
hyperlacatemia, arrhythmias, and decrease in splanchnic 
circulation. In porcine models, epinephrine has been 
shown to cause a signiﬁ   cant reduction in intestinal 
mucosal pH along with signiﬁ  cant mucosal damage as 
early as the ﬁ   rst three hours [2]. Similarly, in human 
studies, epinephrine has been shown to decrease frac-
tional splanchnic blood ﬂ   ow [3], increase splanchnic 
oxygen utilization and CO2 production, and alter acid 
base balance. In view of the important role of the 
integrity of the intestinal epithelium in development of 
multiple organ dysfunction syndrome and the eﬀ  ects of 
epinephrine on splanchnic circulation, epinephrine was 
not considered ﬁ   rst-line therapy [4]. However, some 
studies have suggested that these eﬀ  ects are transient [5]. 
Previously, no large comparative trial had been performed.
Annane and colleagues conducted a double-blind 
randomized controlled trial to compare epinephrine to 
norepinephrine and dobutamine (whenever needed) in 
septic shock [1]. Th  eirs was a moderate-sized, well-
designed study with clinically important endpoints. Th  e 
two treatment groups were well balanced at baseline 
except that the median age was slightly higher in the 
epinephrine group than in the norepinephrine plus 
dobutamine group. Unfortunately, no diﬀ  erences  were 
seen in short- or long-term mortality, hemodynamic 
stabilization, resolution of organ dysfunction, or adverse 
events. In addition, epinephrine did not induce excessive 
cardiovascular adverse eﬀ   ects, including arrhythmias, 
stroke, or acute coronary events, as compared to 
norepinephrine.
A few weaknesses of the study merit consideration. 
First, the study was powered to demonstrate an absolute 
risk reduction in 28-day mortality of 20%. Very few 
interventions in critical care reduce mortality by this 
magnitude. Instead, this study demonstrated a non-
signiﬁ  cant 6% diﬀ  erence in mortality (34% for subjects 
receiving norepinephrine and dobutamine compared to 
40% for subjects receiving epinephrine), similar to 
mortality reduction seen with activated protein C. 
Second, a large number of subjects (1261/1591) screened 
for the study were not enrolled, thereby limiting the 
generalizability of the study. Th   ird, by design, all subjects 
had some exposure to vasopressors prior to enrollment, 
including >15 μg/kg/min of dopamine or any dose of 
epinephrine or norepinephrine. Th  is exposure, though 
less than 24 hours, may have confounded the eﬀ  ects of 
vasoactive agents and the ability to detect a diﬀ  erence in 
outcomes.
Recommendation
In conclusion, this study is unlikely to change current 
recommendations for use of vasoactive agents in septic 
shock. Although cardiovascular adverse eﬀ  ects  were 
similar for epinephrine and norepinephrine with dobuta-
mine, the study was not adequately powered to assess 
small diﬀ   erences in mortality. Th  e non-signi  ﬁ    cantly 
higher mortality for subjects receiving epinephrine high-
lights the need to conduct larger studies before con-
sidering epinephrine as a ﬁ  rst line agent for manage  ment 
of septic shock.
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